Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).
Dirk Arnold
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Ullrich Graeven
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche; Sanofi
Christian A. Lerchenmuller
No relevant relationships to disclose
Brigitta Killing
No relevant relationships to disclose
Reinhard Depenbusch
No relevant relationships to disclose
Claus-Christoph Steffens
Consultant or Advisory Role - Roche
Honoraria - Roche
Salah-Eddin Al-Batran
No relevant relationships to disclose
Thoralf Lange
No relevant relationships to disclose
Georg Dietrich
No relevant relationships to disclose
Jan Stoehlmacher
Consultant or Advisory Role - Roche
Honoraria - Roche
Andrea Tannapfel
No relevant relationships to disclose
Hans-Joachim Schmoll
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Anke Reinacher-Schick
Consultant or Advisory Role - Roche
Honoraria - Roche
Susanna Hegewisch-Becker
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche